Study of FORTEO Use in Subjects in the Community Setting

Completed

Conditions studied: Osteoporosis

In brief

The purpose of this study is to evaluate the long-term effectiveness, safety, and tolerability of FORTEO in a larger, more diverse "real world" population than studied in clinical trials

Key facts

Study ID

NCT01078805

Run by

Eli Lilly and Company

People needed

4167

Starts

2003-08-01

Expected to finish

2011-02-01

Last updated by the study team

2012-06-26

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women who are judged by the study physician to be suitable for FORTEO therapy. The FORTEO product labeling specifies those individuals diagnosed with osteoporosis who are considered to be at high risk for fracture

You may not qualify if…

• Subjects who have an increased baseline risk for osteosarcoma. These include Paget's disease of bone, pediatric populations and young adult patients with open epiphyses, prior external beam or implant radiation therapy involving the skeleton
• Subjects who have administered FORTEO or PTH therapy for more than two weeks directly before study entry
• Subjects who have completed a course of FORTEO or PTH therapy of at least 18 months duration before study entry

Where it is running

• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Lakewood, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.